Regeneron gets long-awaited FDA okay for myeloma drug
Regeneron's bid to join the US market for BCMA-targeted bispecific antibodies for multiple myeloma has finally been realised after the FDA approved its Lynozyfic drug at a second attempt. Lynozyfic (linvoseltamab) has been given accelerated approval by …